Home・Elenco Azioni・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Chiusa

SettoreSettore sanitario

18.8 4.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.86

Massimo

18.69

Metriche Chiave
By Trading Economics
Entrata	-4.9M 326M
Vendite	-330M 401M
P/E Media del settore	42.919 57.371
EPS	0.42
Margine di Profitto	81.263
Dipendenti	835
EBITDA	-345M 30M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+21.71% upside

Dividendi
By Acuity
Utili prossimi	2 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	244M 1.9B
Apertura precedente	14.53
Chiusura precedente	18.8

Notizie sul Sentiment di mercato

By Acuity

50%

147 / 340 Classifica in Healthcare

Sarepta Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20 ago 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19 ago 2026, 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18 ago 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17 ago 2026, 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14 ago 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13 ago 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12 ago 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11 ago 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10 ago 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7 ago 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

6 ago 2026, 20:03 UTC

Social Media

News

Sarepta Therapeutics shares are higher following strong Q2 results, with adjusted EPS of $0.64 and revenue of $401.3 million exceeding estimates.

5 ago 2026, 23:11 UTC

News

Social Media

Sarepta Therapeutics reported Q2 adjusted EPS of $0.64, exceeding estimates. Revenue reached $401.3 million, driving shares higher in after-market trading.

4 ago 2026, 19:31 UTC

Sarepta Therapeutics is higher today, benefiting from strong tech stock performance and increased U.S. manufacturing activity, despite pulling back earlier in the session.

3 ago 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are higher today, reflecting broader market strength. The S&P 500 and Nasdaq 100 have also advanced during the session.

30 lug 2026, 19:58 UTC

Sarepta Therapeutics Inc shares are lower today, with no specific news driving the decline. The stock is trading significantly below its 20-day moving average.

29 lug 2026, 22:06 UTC

News

Sarepta Therapeutics granted inducement stock options to CEO Dr. Michael Severino, with shares trading higher in after-market hours following the announcement.

28 lug 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours amid a broader market decline, with no specific news identified to explain the movement.

27 lug 2026, 23:16 UTC

Social Media

Sarepta Therapeutics appoints Michael Severino as CEO, effective July 28. Shares are higher in after-market trading following the leadership change.

21 lug 2026, 17:51 UTC

Sarepta Therapeutics shares are lower today, pulling back from earlier session highs amid no specific news. The stock remains near the lower end of its one-month range.

Confronto tra pari

Modifica del prezzo

Sarepta Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

21.71% in crescita

Previsioni per 12 mesi

Media 22.87 USD 21.71%

Alto 38 USD

Basso 5 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sarepta Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

16 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 16 che hanno fornito valutazioni azionarie a Sarepta Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

147 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.